(Q48828353)

15 February 2018

title

Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers. (English)

1 reference

15 February 2018

1 reference

2

1 reference

15 February 2018

Gabor Halmos

9

Gabor Halmos

1 reference

15 February 2018

Norman L Block

8

Norman L Block

1 reference

15 February 2018

Anna Klukovits

1

Anna Klukovits

1 reference

15 February 2018

Irving Vidaurre

4

Irving Vidaurre

1 reference

15 February 2018

Luca Szalontay

3

Luca Szalontay

1 reference

15 February 2018

author name string

Andrea Papadia

5

1 reference

15 February 2018

Marta Zarandi

6

1 reference

15 February 2018

Jozsef L Varga

7

1 reference

15 February 2018

language of work or name

English

0 references

publication date

12 July 2011

1 reference

15 February 2018

published in

Cancer

1 reference

15 February 2018

volume

118

1 reference

15 February 2018

issue

3

1 reference

15 February 2018

page(s)

670-680

1 reference

15 February 2018

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

Angiogenesis as a strategic target for ovarian cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

The effect of GHRH antagonists on human glioblastomas and their mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

Synthesis and in vitro evaluation of new potent antagonists of growth hormone-releasing hormone (GH-RH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

Determination of subcutaneous tumor size in athymic (nude) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

Bevacizumab toxicities and their management in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

Immunohistochemical study about the Flt-1/VEGFR1 expression in the gastrointestinal tract of mouse, rat, dog, swine and monkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

Multivisceral cytoreductive surgery in FIGO stages IIIC and IV epithelial ovarian cancer: results and 5-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

7 January 2021

Carcinoma of the Ovary

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

7 January 2021

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

7 January 2021

Bevacizumab in the treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

7 January 2021

Inhibition of growth and reduction in tumorigenicity of UCI-107 ovarian cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26291

7 January 2021

Identifiers

DOI

10.1002/CNCR.26291

1 reference

15 February 2018

PubMed ID

21751186

1 reference

15 February 2018